In the context of PARP inhibitors, it was shown that in TNBC (triple-negative breast cancer) pre-clinical models, olaparib treatment induced CD8+ T-cell infiltration and activation that was necessary for its anti-tumor activity [73]. This evidence concerns the gene CD8A and neoplasm.